Literature DB >> 15557522

Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years.

H Russmann1, J Ghika, J-G Villemure, B Robert, J Bogousslavsky, P R Burkhard, F J G Vingerhoets.   

Abstract

The effects of subthalamic nucleus deep brain stimulation were studied in 52 consecutive patients (13 over age 70, 15 under age 60, 24 age 60 to 70). All groups had improvement of motor fluctuations and dyskinesia. Patients over age 70 had worsening of Unified Parkinson's Disease Rating Scale motor scores on medication, despite less medication reduction. Their activities of daily living and axial subscores worsened, particularly in those with preoperative gait difficulties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557522     DOI: 10.1212/01.wnl.0000144198.26309.d8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 2.  Axial disability and deep brain stimulation in patients with Parkinson disease.

Authors:  Alfonso Fasano; Camila C Aquino; Joachim K Krauss; Christopher R Honey; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2015-01-13       Impact factor: 42.937

3.  Bilateral Subthalamic Nucleus Deep Brain Stimulation in Elderly Patients With Parkinson Disease: A Case-Control Study.

Authors:  Kyle T Mitchell; John R Younce; Scott A Norris; Samer D Tabbal; Joshua L Dowling; Keith M Rich; Joel S Perlmutter; Mwiza Ushe
Journal:  Oper Neurosurg (Hagerstown)       Date:  2020-09-01       Impact factor: 2.703

Review 4.  Advanced stages of PD: interventional therapies and related patient-centered care.

Authors:  Rejko Krüger; Rüdiger Hilker; Christian Winkler; Michael Lorrain; Matthias Hahne; Christoph Redecker; Paul Lingor; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2015-07-03       Impact factor: 3.575

5.  A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.

Authors:  Catherine L Gallagher; Sterling C Johnson; Barbara B Bendlin; Moo K Chung; James E Holden; Terrence R Oakes; Benjamin R Brooks; Richard A Konopacki; Selami Dogan; James H Abbs; Guofan Xu; Robert J Nickles; Robert W Pyzalski; Onofre T Dejesus; W Douglas Brown
Journal:  Brain Imaging Behav       Date:  2011-09       Impact factor: 3.978

Review 6.  Improving long term patient outcomes from deep brain stimulation for treatment-refractory obsessive-compulsive disorder.

Authors:  Andrew Guzick; Patrick J Hunt; Kelly R Bijanki; Sophie C Schneider; Sameer A Sheth; Wayne K Goodman; Eric A Storch
Journal:  Expert Rev Neurother       Date:  2019-11-22       Impact factor: 4.618

7.  Deep brain stimulation for Parkinson's disease and other movement disorders: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

8.  Medication and subthalamic nucleus deep brain stimulation similarly improve balance and complex gait in Parkinson disease.

Authors:  Marie E McNeely; Gammon M Earhart
Journal:  Parkinsonism Relat Disord       Date:  2012-08-10       Impact factor: 4.891

9.  Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation.

Authors:  Stelvio Sestini; Alberto Pupi; Franco Ammannati; Silvia Ramat; Sandro Sorbi; Roberto Sciagrà; Luigi Mansi; Antonio Castagnoli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.